Intravesical Lactobacillus for Urinary Symptoms Among People with NLUTD Who Use Indwelling Catheters

Launched by MEDSTAR HEALTH RESEARCH INSTITUTE · Mar 25, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a potential treatment for people who have neurogenic bladder issues and use indwelling catheters. Researchers want to find out if a specific type of bacteria, called Lactobacillus Rhamnosus GG, can help reduce urinary symptoms and improve overall bladder health. They aim to understand how much of this bacteria is needed to make a difference in urinary symptoms and to learn more about the urine's health and bacteria levels in participants.

To be eligible for the trial, participants need to have had neurogenic bladder for at least six months and use a catheter to manage their bladder. Women must be premenopausal and not currently menstruating. It's important to note that individuals who have been on certain antibiotics or are participating in other studies may not qualify. Those who join the trial can expect to receive the Lactobacillus treatment and help researchers learn more about urinary health, which could lead to better options for managing bladder symptoms in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Neurogenic bladder for at least 6 months;
• • Utilizing indwelling catheterization for bladder management;
• • Women must be premenopausal and not currently menstruating;
• • Community dwelling
• • physical disability
• Exclusion Criteria:
• • Use of prophylactic antibiotics;
• • Instillation of intravesical antimicrobials to prevent UTI;
• • Psychologic or psychiatric conditions influencing the ability to follow instructions;
• • Use of oral or IV antibiotics within the past 2 weeks;
• • Sexual activity within the previous 72 hours;
• • Participation in another study with which results could be confounded.